Research progress of CAR⁃T combined immunomodulator in the treatment of solid tumors DONG Jiayi, CHEN Size,SHAO Lijuan,SONG Minghan. Abstract Abstract: Chimeric antigen receptor(CAR)T cell therapy is a new immunotherapy in the field of tumors. Due to the immunosuppressive microenvironment and ...
Research Progress of CAR-T Therapy in Solid Tumor Treatment CAR-T cell therapy research has developed rapidly in recent years, largely based on the remarkable efficacy of CAR-T therapy in hematological malignancies, and scientists are moving quickly to apply this innovative immunotherapy to the tre...
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung The efficacy of CAR-T cells is hindered by the immunosuppressive microenvironment of solid tumors. Here the authors report the design and characterization of anti-PD-L1-expressing inhalable...
The principle of chimeric antigen receptor T-cell (CAR-T) therapy involves genetically modifying T cells to specifically recognize distinct targets on the tumor cell surface, thereby inducing cytotoxic effects. CAR-T therapy has become a major focus of immunotherapy research for malignant tumors in r...
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies. Transplant Cell Ther. 2024;30:171–86. https://doi.org/10.1016/j.jtct.2023.10.013. Article PubMed CAS Google Scholar Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, Hagag N,...
The focus of cancer treatment has recently shifted towards targeted therapies, including immunotherapy, which allow better individualization of care and are hoped to increase the probability of success for patients. Specifically, T cells genetically modified to express chimeric antigen receptors (CARs; CAR...
. New data show that lactate fermentation, a characteristic of solid tumors, promotes the uptake of lactate into T cells via the monocarboxylate transporter MCT11, which reduces the metabolic fitness and anti-tumor function of these cells, an effect that might be targeted by immunotherapy....
Immune checkpoint inhibitors, as an emerging immunotherapy, have sparked a wave in many tumor treatment studies and have made significant clinical progress. Among them, PD-1/PD-L1 axis has garnered extensive research interest. At present, PD-1/PD-L1 immune checkpoint inhibitors have been ...
most MM patients typically have a median life expectancy of only four to five years after starting treatment. In recent developments, the success of chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies exemplifies a new paradigm shift in advanced immunotherapy techniques with promi...
Key words:chimeric antigen receptor T?cell immunotherapy,,pancreatic cancer,,target,,challenge,combination therapy Cite this article TIAN Jing, ZHANG Zhiyong, BAI Tiankai, YAN Bin.. CAR ⁃T therapy for pancreatic cancer:Research progress and prospects[J]. The Journal of Practical Medicine, 2022,...